Skip to main content
CL

Cindy L. Amundsen

🏥 Duke University, Durham, NC
Trainees (8)
Nazema Siddiqui · 2010Amie Kawasaki · 2012Jennifer Bickhaus · 2018Monique Vaughan · 2019A. Rebecca Meekins · 2020Whitney K. Hendrickson-Cahill · 2021Michele O'Shea · 2022Douglas Luchristt · 2023

Biography​

Amundsen received an MD from the University of Tennessee College of Medicine in 1991 and completed an obstetrics and gynecology residency in Houston in 1995.12 Amundsen completed a female urology fellowship at the University of Texas Medical Center in Houston in 1996, working with Edward McGuire.12 Amundsen is program director of Duke's KURe career development program and formerly directed its urogynecology and reconstructive pelvic surgery fellowship.34

Contributions​

Amundsen's cited work covers sacral and implantable tibial neuromodulation for overactive bladder or urgency urinary incontinence, including device outcomes and lead placement. It also compares sacral neuromodulation with onabotulinumtoxinA for refractory urgency urinary incontinence through the ROSETTA trial and follow-up analyses.56789

Cited on WARWIKI

11 publications with Cindy L. Amundsen as a listed author are cited on WARWIKI, ordered by the number of pages that cite them. Papers whose author list is shortened to "et al." before this name are not included.

  1. Amundsen CL, Richter HE, Menefee SA, et al. "OnabotulinumtoxinA vs sacral neuromodulation on refractory urgency urinary incontinence in women: a randomized clinical trial." JAMA. 2016;316(13):1366–1374. doi
    Cited on: Botulinum Toxin (Neuromodulation Adjunct) · Medtronic InterStim — Sacral Neuromodulation · Intradetrusor OnabotulinumtoxinA
  2. Amundsen CL, Sutherland SE, Kielb SJ, Dmochowski RR. Sacral and Implantable Tibial Neuromodulation for the Management of Overactive Bladder: A Systematic Review and Meta-Analysis. Advances in Therapy. 2025;42(1):10-35. doi
    Cited on: Axonics Sacral Neuromodulation Systems · Revi — Implantable Tibial Neuromodulation · Implantable Tibial Nerve Stimulation (iTNM)
  3. Amundsen CL, Sutherland SE, Heesakkers JPFA, et al. Three-Year Efficacy and Safety of Revi Implantable Tibial Neuromodulation From the Pivotal OASIS Study. The Journal of Urology. 2026;216(2):219-229. doi
    Cited on: Revi — Implantable Tibial Neuromodulation · Implantable Tibial Nerve Stimulation (iTNM)
  4. Luchristt D, Amundsen CL. "Strategies for Difficult Fluoroscopic Landmarking During Sacral Neuromodulation Lead Placement." Urology. 2023;174:218-220. doi
    Cited on: Percutaneous Nerve Evaluation · Sacral Neuromodulation
  5. Harvie HS, Amundsen CL, Neuwahl SJ, et al. Cost-Effectiveness of Sacral Neuromodulation Versus OnabotulinumtoxinA for Refractory Urgency Urinary Incontinence: Results of the ROSETTA Randomized Trial. The Journal of Urology. 2020;203(5):969-977. doi
    Cited on: Medtronic InterStim — Sacral Neuromodulation · Sacral Neuromodulation
  6. Amundsen CL, Komesu YM, Chermansky C, et al. Two-Year Outcomes of Sacral Neuromodulation Versus OnabotulinumtoxinA for Refractory Urgency Urinary Incontinence: A Randomized Trial. European Urology. 2018;74(1):66-73. doi
    Cited on: Medtronic InterStim — Sacral Neuromodulation · Sacral Neuromodulation
  7. Hendrickson WK, Amundsen CL. "Sacral Neuromodulation: Sacral Anatomy and Optimal Lead Placement." Int Urogynecol J. 2021;32(9):2545-2547. doi
    Cited on: Percutaneous Nerve Evaluation
  8. Richter HE, Amundsen CL, Erickson SW, et al. "Characteristics associated with treatment response and satisfaction in women undergoing onabotulinumtoxinA and sacral neuromodulation for refractory urgency urinary incontinence." J Urol. 2017;198(4):890–896. doi
    Cited on: Botulinum Toxin (Neuromodulation Adjunct)
  9. Dieter AA, Amundsen CL, Edenfield AL, et al. "Oral Antibiotics to Prevent Postoperative Urinary Tract Infection: A Randomized Controlled Trial." Obstet Gynecol. 2014;123(1):96–103. doi
    Cited on: Urine Studies
  10. South MM, Foster RT, Webster GD, Weidner AC, Amundsen CL. Surgical excision of eroded mesh after prior abdominal sacrocolpopexy. Am J Obstet Gynecol. 2007;197(6):615.e1–5. doi
    Cited on: Mesh Complications & Removal — POP and SUI Mesh
  11. Amundsen CL, Visco AG, Ruiz H, Webster GD. Outcome in 104 pubovaginal slings using freeze-dried allograft fascia lata from a single tissue bank. Urology. 2000;56(6 Suppl 1):2-8. doi
    Cited on: Tutoplast-Processed Allografts

Footnotes​

  1. Cindy L. Amundsen, MD. Duke Health. Accessed October 2026. ↩ ↩2

  2. dr amundsen continence care champion interview. HCP. Accessed October 2026. ↩ ↩2

  3. The KURe Career Development Program. Duke Department of Obstetrics and Gynecology. Accessed October 2026. ↩

  4. KURe Mentors. Duke Department of Obstetrics and Gynecology. Accessed October 2026. ↩

  5. Amundsen CL, Richter HE, Menefee SA, et al. "OnabotulinumtoxinA vs sacral neuromodulation on refractory urgency urinary incontinence in women: a randomized clinical trial." JAMA. 2016;316(13):1366–1374. doi:10.1001/jama.2016.14617 ↩

  6. Amundsen CL, Sutherland SE, Kielb SJ, Dmochowski RR. Sacral and Implantable Tibial Neuromodulation for the Management of Overactive Bladder: A Systematic Review and Meta-Analysis. Advances in Therapy. 2025;42(1):10-35. doi:10.1007/s12325-024-03019-0 ↩

  7. Amundsen CL, Komesu YM, Chermansky C, et al. Two-Year Outcomes of Sacral Neuromodulation Versus OnabotulinumtoxinA for Refractory Urgency Urinary Incontinence: A Randomized Trial. European Urology. 2018;74(1):66-73. doi:10.1016/j.eururo.2018.02.011 ↩

  8. Harvie HS, Amundsen CL, Neuwahl SJ, et al. Cost-Effectiveness of Sacral Neuromodulation Versus OnabotulinumtoxinA for Refractory Urgency Urinary Incontinence: Results of the ROSETTA Randomized Trial. The Journal of Urology. 2020;203(5):969-977. doi:10.1097/ju.0000000000000656 ↩

  9. Amundsen CL, Sutherland SE, Heesakkers JPFA, et al. Three-Year Efficacy and Safety of Revi Implantable Tibial Neuromodulation From the Pivotal OASIS Study. The Journal of Urology. 2026;216(2):219-229. doi:10.1097/ju.0000000000005062 ↩